Movicol (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol 3350 is a high‑molecular‑weight polyethylene glycol that is not absorbed from the gut. It draws water into the intestinal lumen through osmotic pressure, increasing stool water content and volume. The softened, bulkier stool stimulates peristalsis, facilitating easier passage and relieving constipation.

The dose of Movicol is individualized by the prescribing clinician. Factors such as the severity of constipation, patient age, weight, renal function, and response to therapy influence the amount and frequency. Patients should follow the specific instructions provided by their healthcare provider and the product label.

Data on the safety of Movicol in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their obstetrician or healthcare professional.

To order Movicol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Movicol belongs to the osmotic laxative class, which works by retaining water in the bowel. This differs from stimulant laxatives that increase intestinal motility, and bulk‑forming agents that add fiber. Osmotic agents like Movicol often provide a gentler, more predictable effect on stool consistency and are useful when rapid softening is needed.

Movicol should be stored at ambient temperature, below 25 °C, in its original container. Keep the package tightly closed to protect the powder from moisture and heat. Do not store in the refrigerator or freezer, and keep out of reach of children.

Movicol is supplied as a powder that must be dissolved in water before ingestion. The patient mixes the prescribed amount of powder with the recommended volume of water, stirring until fully dissolved, and then drinks the solution. It is taken orally, usually once daily or as directed by a healthcare professional.

Serious risks associated with Movicol include severe electrolyte disturbances such as hyponatremia or hypokalemia, especially in patients with renal impairment or those taking diuretics. Rare but important reactions include allergic responses (rash, angioedema) and significant dehydration. Any signs of severe abdominal pain, persistent diarrhea, or unusual bleeding should prompt immediate medical evaluation.

Movicol should be avoided in individuals with known hypersensitivity to macrogol or any of its components, in patients with complete bowel obstruction, and in those with severe renal or hepatic impairment unless closely monitored. Caution is also advised for the elderly, patients on electrolyte‑altering medications, and anyone with uncontrolled electrolyte disorders.